Press Releases

Year

July 8, 2021

Beam Therapeutics to Participate in the 2021 William Blair Biotech Focus Conference

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 William Blair

June 30, 2021

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases

Collaboration combines Apellis’ expertise in complement, a complex biological system, with Beam’s proprietary base editing platform Companies will collaborate on six research programs directed to tissues modulated by the complement system, including the eye, liver, and brain WALTHAM, Mass.

May 25, 2021

Beam Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 Jefferies

May 11, 2021

Beam Therapeutics Presents LNP Formulation Data at ASGCT and Reports First Quarter 2021 Financial Results

Data from Beam’s Novel LNP-mRNA Formulation Demonstrates In Vivo Editing in Liver Cells of Non-human Primates Up to 52% Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc.

April 27, 2021

Beam Therapeutics Announces Oral and Poster Presentations at 24th American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present data highlighting its proprietary base editing approach in several

April 20, 2021

Beam Therapeutics Publishes Data Highlighting Ability to Rationally Design Base Editors for Precise Editing

Data Published in The CRISPR Journal Describe Inlaid Base Editors (IBEs) that Enhance Editing Efficiency and Capability, an Advancement of the Company’s Pioneering Work in Developing Base Editors Data Demonstrates Utility of IBEs in BEAM-102, Enabling Conversion of Sickle Cell Hemoglobin Allele to

March 15, 2021

Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results

Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021 Acquisition of Guide Therapeutics Supports Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing Team Bolstered by Appointment of Amy Simon, M.D., as Chief Medical Officer and Kate Walsh to Board of Directors

March 15, 2021

Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that drug development expert Amy Simon, M.D., has been appointed as the company’s chief medical officer.

March 4, 2021

Beam Therapeutics to Participate in the Barclays 2021 Global Healthcare Conference

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Barclays 2021

February 23, 2021

Beam Therapeutics Announces Acquisition of Guide Therapeutics

GuideTx’s Proprietary LNP Screening Technology and Lipid Library Supports Expanded Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Investor Center

Investors & Media

Stockholder Tools

Press Releases

Press Releases

Investors & Media

Stockholder Tools